Network analysis-guided drug repurposing strategies targeting LPAR receptor in the interplay of COVID, Alzheimer’s, and diabetes
Dicson Sheeja Malar, Kanika Verma, Mani Iyer Prasanth, Tewin Tencomnao, James Michael Brimson
Scientific Reports, doi:10.1038/s41598-024-55013-9
The COVID-19 pandemic caused by the SARS-CoV-2 virus has greatly affected global health. Emerging evidence suggests a complex interplay between Alzheimer's disease (AD), diabetes (DM), and COVID-19. Given COVID-19's involvement in the increased risk of other diseases, there is an urgent need to identify novel targets and drugs to combat these interconnected health challenges. Lysophosphatidic acid receptors (LPARs), belonging to the G protein-coupled receptor family, have been implicated in various pathological conditions, including inflammation. In this regard, the study aimed to investigate the involvement of LPARs (specifically LPAR1, 3, 6) in the tri-directional relationship between AD, DM, and COVID-19 through network analysis, as well as explore the therapeutic potential of selected anti-AD, anti-DM drugs as LPAR, SPIKE antagonists. We used the Coremine Medical database to identify genes related to DM, AD, and COVID-19. Furthermore, STRING analysis was used to identify the interacting partners of LPAR1, LPAR3, and LPAR6. Additionally, a literature search revealed 78 drugs on the market or in clinical studies that were used for treating either AD or DM. We carried out docking analysis of these drugs against the LPAR1, LPAR3, and LPAR6. Furthermore, we modeled the LPAR1, LPAR3, and LPAR6 in a complex with the COVID-19 spike protein and performed a docking study of selected drugs with the LPAR-Spike complex. The analysis revealed 177 common genes implicated in AD, DM, and COVID-19. Protein-protein docking analysis demonstrated that LPAR (1,3 & 6) efficiently binds with the viral SPIKE protein, suggesting them as targets for viral infection. Furthermore, docking analysis of the anti-AD and anti-DM drugs against LPARs, SPIKE protein, and the LPARs-SPIKE complex revealed promising candidates, including lupron, neflamapimod, and nilotinib, stating the importance of drug repurposing in the drug discovery process. These drugs exhibited the ability to bind and inhibit the LPAR receptor activity and the SPIKE protein and interfere with LPAR-SPIKE protein interaction. Through a combined network and targeted-based therapeutic intervention approach, this study has identified several drugs that could be repurposed for treating COVID-19 due to their expected interference with LPAR(1, 3, and 6) and spike protein complexes. In addition, it can also be hypothesized that the co-administration of these identified drugs during COVID-19 infection may not only help mitigate the impact of the virus but also potentially contribute to the prevention or management of post-COVID complications related to AD and DM.
Competing interests The authors declare no competing interests.
References
Agu, Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management, Sci. Rep
Babalola, A randomized controlled trial of ivermectin monotherapy versus hydroxychloroquine, ivermectin, and azithromycin combination therapy in COVID-19 patients in Nigeria,
doi:10.21203/rs.3.rs-950352/v1Balan, Neurosteroid allopregnanolone (3α,5α-THP) inhibits inflammatory signals induced by activated MyD88-dependent toll-like receptors, Transl. Psychiatry
Barge, Jade, Gosavi, Talukdar, Borah, In-silico screening for identification of potential inhibitors against SARS-CoV-2 transmembrane serine protease 2 (TMPRSS2), Eur. J. Pharm. Sci
Barnes-Vélez, Aksoy Yasar, Hu, Myelin lipid metabolism and its role in myelination and myelin maintenance, Innovation
Baxendale, Hayward, Ley, Tranmer, Pharmaceutical strategy and innovation: An academics perspective, ChemMedChem
Bhattarai, The ATX-LPA axis regulates vascular permeability during cerebral ischemic-reperfusion, Int. J. Mol. Sci
Bhowmick, COVID-19 and androgen-targeted therapy for prostate cancer patients, Endocr. Relat. Cancer
Biessels, Kappelle, Increased risk of Alzheimer's disease in Type II diabetes: Insulin resistance of the brain or insulininduced amyloid pathology?, Biochem. Soc. Trans
Bouhrara, Evidence of demyelination in mild cognitive impairment and dementia using a direct and specific magnetic resonance imaging measure of myelin content, Alzheimers Dement
Bramante, Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19, N. Engl. J. Med
Brimson, Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: The possible role of the sigma-1 receptor and autophagy, Expert Opin. Ther. Targets
Castilla-Ortega, 1-Oleoyl lysophosphatidic acid: A new mediator of emotional behavior in rats, PLoS One
Castilla-Ortega, Aggravation of chronic stress effects on hippocampal neurogenesis and spatial memory in LPA 1 receptor knockout mice, PLoS One
Choudhary, Gupta, Sharma, Parmar, Therapeutically effective covalent spike protein inhibitors in treatment of SARS-CoV-2, J. Proteins Proteom
Cummings, Alzheimer's disease drug development pipeline: 2022, Alzheimers Dement
D' Alessandro, Serum proteomics in COVID-19 patients: Altered coagulation and complement status as a function of IL-6 level, J. Proteome Res
Dawson, Hotchin, Lax, Rumsby, Lysophosphatidic acid induces process retraction in CG-4 line oligodendrocytes and oligodendrocyte precursor cells but not in differentiated oligodendrocytes, J. Neurochem
Edmiston, Bej, Wilson, Jump, Phillips, Donepezil-associated survival benefits among Alzheimer's disease patients are retained but not enhanced during COVID-19 infections, Ther. Adv. Infect. Dis
Eswar, Tools for comparative protein structure modeling and analysis, Nucleic Acids Res
Fayyaz, Lysophosphatidic acid inhibits insulin signaling in primary rat hepatocytes via the LPA3 receptor subtype and is increased in obesity, Cell Physiol. Biochem
Feingold, Oral and injectable (non-insulin) pharmacological agents for the treatment of type 2 diabetes
García-Díaz, Loss of lysophosphatidic acid receptor LPA(1) alters oligodendrocyte differentiation and myelination in the mouse cerebral cortex, Brain Struct. Funct
Geraldo, Role of lysophosphatidic acid and its receptors in health and disease: Novel therapeutic strategies, Signal Transduct. Target Ther
Goldstein, Speth, Trivedi, Renin-angiotensin system gene expression and neurodegenerative diseases, J. Renin Angiotensin Aldosterone Syst
Guex, Peitsch, SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling, Electrophoresis
Guo, Diabetes is a risk factor for the progression and prognosis of COVID-19, Diabetes Metab. Res. Rev
Gómez, Binding of SARS-CoV-2 to cell receptors: A tale of molecular evolution, Chembiochem
Halgren, Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94, J. Comput. Chem
Hoda, Kramer, Merseburger, Cronauer, Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer, Expert Opin. Pharmacother
Huang, Diabetes mellitus and the risk of Alzheimer's disease: A nationwide population-based study, PLoS One
Kelley, Mezulis, Yates, Wass, Sternberg, The Phyre2 web portal for protein modeling, prediction and analysis, Nat. Protoc
Kouhpayeh, Association between angiotensinogen (AGT), angiotensin-converting enzyme (ACE) and angiotensin-II receptor 1 (AGTR1) polymorphisms and COVID-19 infection in the southeast of Iran: A preliminary case-control study, Transl. Med. Commun
Laskowski, Macarthur, Moss, Thornton, PROCHECK-A program to check the stereochemical quality of protein structures, J. Appl. Cryst
Laskowski, PDBsum 1: A standalone program for generating PDBsum analyses, Protein Sci
Laskowski, Rullmannn, Macarthur, Kaptein, Thornton, AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR, J. Biomol. NMR
Lee, Lysophosphatidic acid receptor 1 inhibitor, AM095, attenuates diabetic nephropathy in mice by downregulation of TLR4/NF-κB signaling and NADPH oxidase, Biochim. Biophys. Acta Mol. Basis Dis
Leon-Abarca, Diabetes increases the risk of COVID-19 in an altitude dependent manner: An analysis of 1,280,806 Mexican patients, PLoS One
Li, Circular RNA expression profile of Alzheimer's disease and its clinical significance as biomarkers for the disease risk and progression, Int. J. Biochem. Cell Biol
Li, Oh, Choi, Jung, Jun, Blocking lysophosphatidic acid receptor 1 signaling inhibits diabetic nephropathy in db/db mice, Kidney Int
Luedemann, Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing, Comput. Struct. Biotechnol. J
Mansoor, Raghif, Attenuated effects of rivastigmine in induced cytokine storm in mice, J. Emerg. Med. Trauma Acute Care
Markov, The evolution of SARS-CoV-2, Nat. Rev. Microbiol
Masago, Lysophosphatidic acid receptor, LPA6, regulates endothelial blood-brain barrier function: Implication for hepatic encephalopathy, Biochem. Biophys. Res. Commun
Mcconkey, Sobolev, Edelman, The performance of current methods in ligand-protein docking, Curr. Sci
Mcdonald, Altered cleavage plane orientation with increased genomic aneuploidy produced by receptor-mediated lysophosphatidic acid (LPA) signaling in mouse cerebral cortical neural progenitor cells, Mol. Brain
Meng, Zhang, Mezei, Cui, Molecular docking: A powerful approach for structure-based drug discovery, Curr. Comput. Aided Drug Des
Mitew, Focal demyelination in Alzheimer's disease and transgenic mouse models, Acta Neuropathol
Moghadasi, Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors, Sci. Adv
Moreno-Fernández, maLPA1-null mice as an endophenotype of anxious depression, Transl. Psychiatry
Muenchhoff, Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer's disease, Sci. Rep
Muhammed, Aki-Yalcin, Homology modeling in drug discovery: Overview, current applications, and future perspectives, Chem. Biol. Drug Des
Mulgaonkar, Montelukast and telmisartan as inhibitors of SARS-CoV-2 omicron variant, Pharmaceutics
Nallur, Interaction of the SARS-COV2 envelope protein (E) with lysophosphatidic acid receptor 1 (LPAR1) and additional human proteins involved in inflammation, immunity, ADP ribosylation and vesicular transport,
doi:10.2139/ssrn.3702607Nguyen, Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis, Metabolism
Noel, Natural aging and Alzheimer's disease pathology increase susceptibility to focused ultrasound-induced bloodbrain barrier opening, Sci. Rep
Rancoule, Lysophosphatidic acid impairs glucose homeostasis and inhibits insulin secretion in high-fat diet obese mice, Diabetologia
Reiken, Alzheimer's-like signaling in brains of COVID-19 patients, Alzheimers Dement
Ribeiro-Oliveira, The renin-angiotensin system and diabetes: an update, Vasc. Health Risk Manag
Roncon, Zuin, Rigatelli, Zuliani, Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome, J. Clin. Virol
Sastry, Adzhigirey, Day, Annabhimoju, Sherman, Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments, J. Comput. Aided Mol. Des
Shi, Chen, Ma, Xu, Deng, Identification of potential biomarkers of depression and network pharmacology approach to investigate the mechanism of key genes and therapeutic traditional Chinese medicine in the treatment of depression, Evid. Based Complement. Alternat. Med
Singh, Computational screening of FDA approved drugs of fungal origin that may interfere with SARS-CoV-2 spike protein activation, viral RNA replication, and post-translational modification: A multiple target approach, Silico Pharmacol
Sodhi, Montaner, Gutkind, Viral hijacking of G-protein-coupled-receptor signalling networks, Nat. Rev. Mol. Cell Biol
Suratanee, Plaimas, DDA: A novel network-based scoring method to identify disease-disease associations, Bioinform. Biol. Insights
Szklarczyk, STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets, Nucleic Acids Res
Tan, Neurological implications of COVID-19: A review of the science and clinical guidance, BMJ Neurol. Open
Vaz, Vassiliades, Giarolla, Polli, Parise-Filho, Drug repositioning in the COVID-19 pandemic: Fundamentals, synthetic routes, and overview of clinical studies, Eur. J. Clin. Pharmacol
Wang, Association of COVID-19 with new-onset Alzheimer's disease, J. Alzheimers Dis
Wang, Chen, Wei, Mechanisms of SARS-CoV-2 evolution revealing vaccine-resistant mutations in Europe and America, J. Phys. Chem. Lett
Wang, Fang, Lu, Wang, HawkDock: A web server to predict and analyze the binding protein hotspots and regulatory hotspots, Bioinformatics
Wiehe, Peterson, Pierce, Mintseris, Weng, Protein-protein docking: Overview and performance analysis, Methods Mol. Biol
Wong, Siah, Lo, Estimation of clinical trial success rates and related parameters, Biostatistics
Wu, Du, Wu, CircLPAR1/miR-212-3p/ZNF217 feedback loop promotes amyloid β-induced neuronal injury in Alzheimer's Disease, Brain Res
Xia, Wang, Zheng, COVID-19 and Alzheimer's disease: How one crisis worsens the other, Transl. Neurodegener
Xiang, Lu, Shao, Wu, Lysophosphatidic acid receptors: Biochemical and clinical implications in different diseases, J. Cancer
Xiao, Comprehensive proteomic profiling of aqueous humor proteins in proliferative diabetic retinopathy, Transl. Vis. Sci. Technol
Xiong, CircLPAR1 promotes neuroinflammation and oxidative stress in APP/PS1 mice by inhibiting SIRT1/Nrf-2/HO-1 axis through destabilizing GDF-15 mRNA, Mol. Neurobiol
Xu, A novel nine-microRNA-based model to improve prognosis prediction of renal cell carcinoma, BMC Cancer
Yamada, Lysophosphatidic acid induces anxiety-like behavior via its receptors in mice, J. Neural Transm
Yan, Tao, He, Huang, The HDOCK server for integrated protein-protein docking, Nat. Protoc
Ye, Exploring the common pathogenesis of Alzheimer's disease and type 2 diabetes mellitus via microarray data analysis, Front. Aging Neurosci
Yung, Stoddard, Mirendil, Chun, Lysophosphatidic acid signaling in the nervous system, Neuron
Zhang, Lysophosphatidic acid receptor antagonism protects against diabetic nephropathy in a type 2 diabetic model, J. Am. Soc. Nephrol
Zhang, Risk for newly diagnosed diabetes after COVID-19: A systematic review and meta-analysis, BMC Med
Zhang, Targeting lysophospholipid acid receptor 1 and ROCK kinases promotes antiviral innate immunity, Sci. Adv
Zhao, Natarajan, Lysophosphatidic acid (LPA) and its receptors: Role in airway inflammation and remodeling, Biochim. Biophys. Acta
